UNCY vs. IMAB, GOSS, MCRB, CTMX, SYRS, RPTX, RGLS, RNAC, NLTX, and FGEN
Should you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include I-Mab (IMAB), Gossamer Bio (GOSS), Seres Therapeutics (MCRB), CytomX Therapeutics (CTMX), Syros Pharmaceuticals (SYRS), Repare Therapeutics (RPTX), Regulus Therapeutics (RGLS), Cartesian Therapeutics (RNAC), Neoleukin Therapeutics (NLTX), and FibroGen (FGEN). These companies are all part of the "pharmaceutical preparations" industry.
Unicycive Therapeutics (NASDAQ:UNCY) and I-Mab (NASDAQ:IMAB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, community ranking, earnings, dividends and profitability.
Unicycive Therapeutics has a beta of 2.72, meaning that its stock price is 172% more volatile than the S&P 500. Comparatively, I-Mab has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.
I-Mab received 35 more outperform votes than Unicycive Therapeutics when rated by MarketBeat users. However, 67.74% of users gave Unicycive Therapeutics an outperform vote while only 62.92% of users gave I-Mab an outperform vote.
Unicycive Therapeutics currently has a consensus price target of $5.30, suggesting a potential upside of 502.27%. I-Mab has a consensus price target of $12.25, suggesting a potential upside of 637.95%. Given I-Mab's higher probable upside, analysts plainly believe I-Mab is more favorable than Unicycive Therapeutics.
In the previous week, Unicycive Therapeutics had 6 more articles in the media than I-Mab. MarketBeat recorded 7 mentions for Unicycive Therapeutics and 1 mentions for I-Mab. I-Mab's average media sentiment score of 1.08 beat Unicycive Therapeutics' score of 0.24 indicating that I-Mab is being referred to more favorably in the news media.
Unicycive Therapeutics has higher earnings, but lower revenue than I-Mab.
40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 38.4% of I-Mab shares are held by institutional investors. 24.1% of Unicycive Therapeutics shares are held by insiders. Comparatively, 22.1% of I-Mab shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Unicycive Therapeutics beats I-Mab on 7 of the 12 factors compared between the two stocks.
Get Unicycive Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Unicycive Therapeutics Competitors List
Related Companies and Tools
